407 related articles for article (PubMed ID: 35175514)
1. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
2. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.
Mete O; Erickson LA; Juhlin CC; de Krijger RR; Sasano H; Volante M; Papotti MG
Endocr Pathol; 2022 Mar; 33(1):155-196. PubMed ID: 35288842
[TBL] [Abstract][Full Text] [Related]
3. Advances and Updates in Parathyroid Pathology.
Gokozan HN; Scognamiglio T
Adv Anat Pathol; 2023 Jan; 30(1):24-33. PubMed ID: 36315270
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid tumors in the 5th edition of the WHO Classification of Tumors of the Endocrine Organs.
J D
Cesk Patol; 2024; 60(1):68-70. PubMed ID: 38697830
[TBL] [Abstract][Full Text] [Related]
5. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
6. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
7. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
9. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
[TBL] [Abstract][Full Text] [Related]
10. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
Ababneh E; Nosé V
Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
[TBL] [Abstract][Full Text] [Related]
11. Parathyroid Pathology.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):1007-1019. PubMed ID: 31672291
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
Parfitt J; Harris M; Wright JM; Kalamchi S
J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
[TBL] [Abstract][Full Text] [Related]
13. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
Cetani F; Marcocci C; Torregrossa L; Pardi E
Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
[TBL] [Abstract][Full Text] [Related]
14. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
[TBL] [Abstract][Full Text] [Related]
15. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.
Cetani F; Pardi E; Ambrogini E; Viacava P; Borsari S; Lemmi M; Cianferotti L; Miccoli P; Pinchera A; Arnold A; Marcocci C
Endocr Relat Cancer; 2007 Jun; 14(2):493-9. PubMed ID: 17639062
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological correlates of hyperparathyroidism.
Duan K; Gomez Hernandez K; Mete O
J Clin Pathol; 2015 Oct; 68(10):771-87. PubMed ID: 26163537
[TBL] [Abstract][Full Text] [Related]
17. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
18. Comparison of quick parathyroid assay for uniglandular and multiglandular parathyroid disease.
Stratmann SL; Kuhn JA; Bell MS; Preskitt JT; O'Brien JC; Gable DR; Stephens JS; McCarty TM
Am J Surg; 2002 Dec; 184(6):578-81; discussion 581. PubMed ID: 12488174
[TBL] [Abstract][Full Text] [Related]
19. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.
Uljanovs R; Sinkarevs S; Strumfs B; Vidusa L; Merkurjeva K; Strumfa I
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]